32097
依托考昔
VETRANAL®, analytical standard
别名:
5-氯-3-[4-(甲磺酰基)苯基]-2-(2-甲基-5-吡啶基)吡啶, 5-氯-6′-甲基-3-[4-(甲磺酰基)苯基]]-2,3′-联吡啶
登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H15ClN2O2S
化学文摘社编号:
分子量:
358.84
Beilstein:
8073797
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
analytical standard
质量水平
产品线
VETRANAL®
保质期
limited shelf life, expiry date on the label
技术
HPLC: suitable
gas chromatography (GC): suitable
应用
forensics and toxicology
pharmaceutical (small molecule)
veterinary
包装形式
neat
储存温度
2-8°C
SMILES字符串
CC1=NC=C(C2=C(C3=CC=C(S(C)(=O)=O)C=C3)C=C(Cl)C=N2)C=C1
InChI
1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
InChI key
MNJVRJDLRVPLFE-UHFFFAOYSA-N
基因信息
human ... PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
一般描述
依托考昔是一种非甾体类环加氧酶-2（COX-2）选择性抗炎药，主要用于骨关节炎和类风湿性关节炎患者的治疗。
应用
依托考昔已被用作参考标准品，用于通过液相色谱-串联质谱-常压化学电离分析法（LC-APCI/MS/MS）检测人血浆中的依托考昔。
有关合适仪器技术的更多信息，请参考产品′s分析证书。如需进一步支持，请联系技术服务。
法律信息
VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险声明
危险分类
Acute Tox. 2 Dermal - Acute Tox. 4 Oral
储存分类代码
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
Klaus Schaffler et al.
British journal of clinical pharmacology, 75(2), 404-414 (2012-07-11)
Laser (radiant-heat) evoked potentials (LEPs) from vertex-EEG peak-to-peak (PtP) amplitude were used to determine acute antinociceptive/antihyperalgesic efficacy of ABT-102, a novel TRPV1 antagonist efficacious in preclinical pain models, compared with active controls and placebo in normal and UV(B)-inflamed skin. This
Deborah J Cochrane et al.
Drugs, 62(18), 2637-2651 (2002-12-06)
Etoricoxib is a cyclo-oxygenase (COX)-2-selective NSAID with a higher COX-1 to COX-2 selectivity ratio than the other COX-2-selective NSAIDs rofecoxib, valdecoxib or celecoxib. In patients with rheumatoid arthritis, improvements in tender and swollen joint counts and patient and investigator global
Rachel Clarke et al.
The Cochrane database of systematic reviews, 4(4), CD004309-CD004309 (2012-04-20)
Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor licensed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis, and acute pain in some jurisdictions. This class of drugs is believed to be associated with fewer upper gastrointestinal adverse effects
Paola Patrignani et al.
Expert opinion on pharmacotherapy, 4(2), 265-284 (2003-02-04)
The development of COX2 inhibitors with improved biochemical selectivity (such as etoricoxib and valdecoxib) over that of commercially available coxibs has been driven by the potential advantage of safety using higher coxib doses for increased efficacy. Etoricoxib has been approved
Rik J Lories
Expert opinion on drug metabolism & toxicology, 8(12), 1599-1608 (2012-11-07)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line therapies in the management of patients with ankylosing spondylitis. This chronic inflammatory skeletal disorder, a subtype of spondyloarthritis, is characterized by inflammatory back pain and affects young adults causing important suffering and disability. Long-term
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持